No support for regional selectivity in clozapine-treated patients: A PET study with [11C]raclopride and [11C]FLB 457

American Journal of Psychiatry

Volumn 158, Issue 6, 2001, Pages 926-930

  Talvik, M ^a   Nordstrom A L ^a   Nyberg, S ^a   Olsson, H ^a   Halldin, C ^a   Farde, L ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; CLOZAPINE; HALOPERIDOL; ISOREMOXIPRIDE; RACLOPRIDE;

ADULT; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; CORPUS STRIATUM; DRUG MECHANISM; FEMALE; FRONTAL CORTEX; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; TEMPORAL CORTEX; THALAMUS;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN; CLOZAPINE; CORPUS STRIATUM; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PYRROLIDINES; RACLOPRIDE; RECEPTORS, DOPAMINE D2; SALICYLAMIDES; SCHIZOPHRENIA; SCHIZOPHRENIA, PARANOID; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034974721     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.158.6.926     Document Type: Article

References (38)

1. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
2. Antipsychotic drug doses and neuroleptic/dopamine receptors
3. Antipsychotic drugs, neurotransmitters, and schizophrenia
4. 2 dopamine receptor binding in the living human brain by PET
5. In vivo assay for neuroleptic receptor binding in the striatum
6. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs
7. 18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients
8. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: Correlative evaluation by positron emission tomography and plasma prolactin levels
9. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine
10. Clozapine: Neuroleptic-induced EPS and tardive dyskinesia
11. Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia
12. Dimensions of outcome with clozapine
13. Clozapine effects on positive and negative symptoms: A six-month trial in treatment-refractory schizophrenics
14. 2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics
15. 2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine - Relation to extrapyramidal side effects
16. 2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients
17. Effect of clozapine on the turnover of dopamine in the corpus striatum and the limbic systems
18. The "neuroleptic" antipsychotic drugs, 1: Mechanisms of action
19. Regional selectivity of neuroleptic drugs: An argument for site specificity
20. 2 receptors: Distribution, pharmacological characterization and region specific regulation by clozapine
21. Neuroanatomical targets of neuroleptic drugs as revealed by Fos immunochemistry
22. 2 dopamine receptors
23. 11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain
24. 11C]raclopride binding to D2-dopamine receptors studied by PET - A comparison to the equilibrium analysis
25. 11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients
26. Limbic selectivity of clozapine
27. Head fixation system for integration of radiodiagnostic and therapeutic procedures
28. A comparative PET-duty of five carbon-11 or fluorine-18 labelled salicylamides: Preparation and in vitro dopamine D-2 receptor binding
29. 11C]methyl triflate
30. The ECAT EXACT HR: Performance of a new high resolution positron scanner
31. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype
32. Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection
33. Simplified reference tissue model for PET receptor studies
34. Measurement error and correlation coefficients
35. RBC and plasma levels of haloperidol and clinical response in schizophrenia
36. Clinical response and plasma haloperidol levels in schizophrenia
37. 3 receptors
38. 76Br]FLB 463 for examination of striatal and extrastriatal dopamine D-2 receptors with PET